Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial

Recurrence rate of hepatocellular carcinoma(HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefore...

Full description

Saved in:
Bibliographic Details
Published in:World journal of hepatology 2016-08, Vol.8 (23), p.957-960
Main Authors: Zhong, Jian-Hong, Du, Xue-Ke, Xiang, Bang-De, Li, Le-Qun
Format: Article
Language:English
Subjects:
Adjuvant
Hepatocellular
carcinoma
Tumor
recurrence
Sorafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recurrence rate of hepatocellular carcinoma(HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefore it stands to reason to expect that adjuvant sorafenib may improve post-surgery outcomes of patients with HCC. However, many questions still exist about the value of sorafenib for patients with HCC after surgery or transarterial chemoembolization. In this editorial, we complehensively reviewed the safety and efficacy of adjuvant sorafenib for patients with hepatocellar carcinoma after surgery or transarterial chemoembolization. We emphasized the positive and negative role of sorafenib.
ISSN:1948-5182
1948-5182
DOI:10.4254/wjh.v8.i23.957